ASTERA LABS INC SEC Filings

Astera Labs insider transfer and holdings update. Director and President/COO Gajendra Sanjay reported transactions on 09/02/2025 moving 480,668 shares of common stock. The filing shows a corresponding reduction in directly held shares to 1,690,209 and an increase in indirectly beneficially owned shares to 6,006,213 held by three estate planning trusts. The Form 4 states the 480,668-share transfers to Trust 1 were for $0 and that Trusts 1–3 each hold 695,000 shares as described; the reporting person disclaims beneficial ownership of trust-held shares except for any pecuniary interest. The filing was signed by an attorney-in-fact on behalf of the reporting person.

Philip Mazzara, General Counsel and Secretary of Astera Labs, Inc. (ALAB), sold 10,000 shares of company common stock on 08/28/2025 under a pre-established Rule 10b5-1 trading plan adopted May 29, 2025. The sales occurred in multiple transactions at prices ranging approximately from $182.55 to $190.91 per share; weighted-average prices are reported for several tranches. Following these dispositions, the reporting person’s beneficial ownership is reported as 161,573 shares, held directly. The Form 4 discloses that the transactions executed automatically under the trading plan.

Astera Labs, Inc. (ALAB) filing a Form 144 notifies a proposed sale of 33,000 common shares through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $6,012,600.00. The shares were acquired 11/30/2018 in a private acquisition from the issuer and paid in cash. The filing lists multiple prior 10b5-1 sales by related trusts and entities between 06/20/2025 and 07/21/2025, including individual sales of 51,000, 58,000, 29,000 and others. The signer represents no undisclosed material adverse information and cites a Rule 10b5-1 trading plan context where applicable.

Form 144 notice for Astera Labs, Inc. (ALAB) reporting a proposed sale of 150,000 common shares through Morgan Stanley Smith Barney on 09/02/2025 on NASDAQ. The filing lists an aggregate market value of $27,330,000 for the block and reports total shares outstanding of 166,219,140. The shares were acquired 03/21/2018 in a private acquisition from the issuer and paid in cash. The filing also discloses multiple Rule 10b5-1 sales by related trusts and entities in the past three months totaling 237,100 shares for gross proceeds of $22,136,140.67. The notice includes the standard attestation that the seller is not aware of undisclosed material adverse information.

Astera Labs (ALAB) submitted a Form 144 notifying the market of a proposed sale of 170,000 common shares through Morgan Stanley Smith Barney, with an aggregate market value of $30,974,000 and an approximate sale date of 09/02/2025. The shares were acquired in a private issuance from the issuer on 03/21/2018 and were paid for in cash. The filing shows total shares outstanding of 166,219,140, and discloses multiple recent Rule 10b5-1 sales by related trusts between 06/20/2025 and 07/21/2025, with individual gross proceeds listed for each transaction. The signer certifies no undisclosed material adverse information and references reliance on planned trading instructions where applicable.

Astera Labs director Jack R. Lazar reported automatic sales of common stock under a Rule 10b5-1 trading plan adopted May 28, 2025. On 08/27/2025 the Form 4 shows five sale transactions totaling 22,500 shares sold in multiple trades at weighted-average prices ranging from about $176.73 to $183.09. The filing lists the reporter's beneficial ownership following the reported sales as 97,351 shares held directly. The Form 4 was signed by an attorney-in-fact on 08/28/2025 and includes footnotes disclosing price ranges for each grouped sale.

Astera Labs, Inc. (ALAB) Form 144 summary: Philip Mazzara filed a notice to sell 20,000 common shares via Morgan Stanley Smith Barney LLC, with an aggregate market value of $3,584,000 and an approximate sale date of 08/28/2025. The shares were acquired on 03/14/2022 through previously exercised stock options and were paid for in cash. The filing reports 166,219,140 shares outstanding for the issuer. It also records a prior sale by the same person of 7,237 shares on 08/18/2025 for gross proceeds of $1,328,064.80. The filer certifies they are not aware of any undisclosed material adverse information about the issuer.

Astera Labs, Inc. (ALAB) submitted a Form 144 notice reporting a proposed sale of 22,500 shares of common stock through UBS Financial Services Inc. on the NASDAQ with an aggregate market value of $4,014,398.25. The filing lists the securities to be sold on 08/27/2025.

The filing shows all 22,500 shares were acquired by the seller through RSU vesting on four dates: 11/15/2024 (2,187), 02/15/2025 (3,438), 05/15/2025 (8,437), and 08/15/2025 (8,438), which together equal the 22,500 shares proposed for sale. The filer reports nothing to report for securities sold in the past three months. The form includes the required signature attestation about absence of undisclosed material adverse information.

Mohan Jitendra, listed as Chief Executive Officer and a director of Astera Labs, Inc. (ALAB), reported an insider transaction dated 08/20/2025. The filing shows a bona fide gift of 150,000 shares of common stock (transaction code G) transferred at a price of $0 to a non‑affiliated entity. Following the reported transactions, the Form 4 lists total indirect beneficial ownership of 4,130,002 shares held across multiple trusts and estate planning vehicles and several other indirect holdings noted in the filing. The Form 4 was signed by an attorney‑in‑fact, Philip Mazzara, on 08/21/2025.